MedSwitcher
FDA-ApprovedInjectable pen (subcutaneous)

Zepbound

tirzepatide · Eli Lilly

Choose your next step

Research the details now, then get alerts and treatment options for Zepbound when you are ready to act.

Get Zepbound pricing and access updates by email

Key Facts

Form

Injectable pen (subcutaneous)

Frequency

Once weekly

Available Doses

2.5mg5mg7.5mg10mg12.5mg15mg

FDA Approval Date

November 8, 2023

Mechanism

Dual GLP-1 + GIP receptor agonist

Manufacturer

Eli Lilly

Cost

Self-Pay

$499/mo flat (all doses) via LillyDirect

With Savings Card

$25/mo for commercially insured patients

List Price

~$1,086/mo

LillyDirect self-pay recently updated to $499/mo flat rate for all doses.

Side Effects

Side EffectRateSource
Nausea~28%SURMOUNT-1, 15mg dose
Diarrhea~23%SURMOUNT-1, 15mg dose
Vomiting~12%SURMOUNT-1, 15mg dose
Constipation~11%SURMOUNT-1, 15mg dose
Injection site reactions~3.2%SURMOUNT-1
Hair loss~5%SURMOUNT-1

Source: SURMOUNT-1 Phase 3 Trial, tirzepatide 15mg, 72 weeks

Weight Loss Results

SURMOUNT-1

~22.5%

72 weeks · Completers analysis

72 weeks

Tirzepatide 15mg vs placebo. Highest weight loss of any single-agent GLP-1 class drug.

SURMOUNT-1

~20.9%

72 weeks · Treatment regimen (ITT)

72 weeks

Treatment regimen estimate — all randomized patients.

How It Works

Zepbound activates both GLP-1 and GIP receptors — two key incretin hormones involved in appetite regulation and metabolism. GLP-1 activation reduces appetite, slows gastric emptying, and improves insulin sensitivity. GIP activation adds complementary metabolic benefits including enhanced fat breakdown and additional appetite suppression. The dual mechanism is why Zepbound achieves higher weight loss than GLP-1-only drugs.

Mechanism: Zepbound (tirzepatide) is the first FDA-approved dual incretin agonist, activating both GLP-1 and GIP receptors. This dual mechanism provides enhanced metabolic effects compared to GLP-1-only drugs, leading to the highest weight loss seen in any single-agent GLP-1 class medication.

Who It's For

Indication

Chronic weight management (obesity or overweight with comorbidities)

Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Best for patients who need maximum weight loss and are comfortable with weekly injections. Lilly recommends patients may later switch to Foundayo for oral maintenance.

Food & Water Restrictions

✅ No Restrictions

This medication can be taken at any time of day, with or without food and water.

Switching Guides

Comparisons

Helpful Articles

Zepbound fact review snapshot
Medication
Zepbound
Tracked facts
12
Human verified
0
Last refreshed: 2026-04-07

This page pulls from MedSwitcher's structured medication fact database. Facts are tracked separately from page copy so we can update sources, pricing, and trial details without guessing.

Primary source trail
  • Zepbound Prescribing Information
  • SURMOUNT-1
  • LillyDirect Zepbound pricing

Want the boring but important details? Read our editorial policy and methodology.

Don't miss price changes

GLP-1 prices are changing — stay ahead

Foundayo prices may increase — get alerts before they do. Track price drops, shortages, and new switching guidance without checking back manually.

  • Price increase warnings before they hit
  • Savings card and coupon alerts
  • New switching guidance and availability updates

No spam. Unsubscribe anytime. We never share your email.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Clinical trial data referenced comes from published studies and FDA prescribing information. Side effect rates are from specific clinical trials and may not reflect real-world experience. Always consult your healthcare provider before starting, stopping, or switching any medication.